Table 4.
Summary of ongoing studies
| PI | NCT | Statusa | Nb | Medication | Follow up | Main outcomes | Results |
|---|---|---|---|---|---|---|---|
| Vaillancourt [45] | NCT03456687 | Completed | 5 | Exenatide | 1 year |
Change in free-water accumulation in the substantia nigra Change in BOL signal in the posterior putamen Change in BOL signal in M1 Change in BOL signal in the SMA |
NA |
| Foltynie [46] | NCT04232969 | Active, not recruiting | 194 | Exenatide | 2 years |
MDS-UPDRS Part III (ON state) MDS-UPDRS Part IV and II (OFF state) PHQ-9 PDQ-39 NMSS |
NA |
| Min Ho Ihm [47] | NCT04269642 | Unknown | 99 | Exenatide SR | 60 weeks |
MDS-UPDRS Part III Specific to non-specific binding ratio (confirmed by PET scan) MDS-UPDRS Part I, II, and IV PDQ-39 MoCA NMSS |
NA |
| NA [48] | NCT03659682 | Not yet recruiting | 120 | Semaglutide | 48 months |
MDS-UPDRS Part III (OFF state) Levodopa equivalents Nigrostriatal degeneration (assessed by changes in DAT-scan uptake) Cognitive function |
NA |
| Svenningsson [49] | NCT04305002 | Unknown | 60 | Exenatide | 21 months |
MDS-UPDRS Part III (ON and OFF states) MDS-UPDRS II and IV Accelerometer (intensity of physical activity) Accelerometer (steps per day) |
NA |
BOL Blood Oxygen Level-dependent, MDR-UPDRS Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease, MMSE Mini-Mental State Examination, MoCA Montreal Cognitive Assessment, NA not available, NMSS National Multiple Sclerosis Society, PHQ-9 Patient Health Questionnaire, PDQ-39 Parkinson’s Disease Questionnaire, PI principal investigator, SR sustained release, SMA Supplementary Motor Area
a The recruitment status as found in the registration protocol of the trials
b The actual enrollment (not the estimated enrollment) as found in the registration protocol of the trials